Overview

Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial

Status:
Completed

Trial end date:
2017-06-02

Target enrollment:
0

Participant gender:
All

Summary

This study aim to evaluate whether intensive lipid lowering therapy may improve the clinical outcomes in coronary artery disease patients with in-stent neoatherosclerosis, in comparison with standard therapy.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kobe University

Treatments:

Rosuvastatin Calcium

Criteria

Inclusion Criteria:

- Consecutive patients with stent implantation who were performed coronary angiography
and OCT follow-up of the coronary arteries were candidate. During this period, OCT was
performed for the following reasons: 1) planned follow-up coronary angiography and OCT
for routine stent follow-up or due to other study protocols, regardless of symptoms;
2) evidence of myocardial ischemia such as silent myocardial ischemia, stable angina,
or acute coronary syndrome; or 3) planned follow-up angiography for other stent
segments. These patients were implanted bare metal stent, sirolimus-eluting stents
(Cypher, Cordis, Miami Lakes, FL, USA), paclitaxel-eluting stents (Taxus, Boston
Scientific, Natick, MA, USA), or everolimus-eluting stents (XIENCE V, Abbott Vascular,
Santa Clara, CA, USA). The investigators assessed their OCT examination at the
follow-up OCT time and patients who were detected NA on OCT findings were eligible for
the presence study.

Exclusion Criteria:

- Exclusion criteria for OCT were 1) anatomically unsuitable target artery for OCT
according to previously described criteria, 10 2) apparent congestive heart failure,
3) renal insufficiency with baseline creatinine level ≥2.0 mg/dL expect for under
hemodialysis, or 4) lack of written informed consent from the patient.